retatrutide nafld Lindsay Maggio, MD, MPH | 📣 News you need to know — is almost here, and the data is remarkable. Eli Lilly just released Phase 3 results for retatrutide, retatrutide nonalcoholic fatty liver disease

It looked at data from more than 100,000 women and found lower rates of breast cancer among those taking the drugs

Where Ozempic (semaglutide) is a pure GLP-1 receptor agonist, Retatrutide is a triple agonist working on: GLP-1 improves insulin sensitivity, reduces appetite, slows stomach emptying GIP (Glucose-dependent insulinotropic peptide) enhances insulin secretion, may preserve beta cells, and appears to help prevent the dreaded weight plateau seen with GLP-1 alone Glucagon receptor promotes fat metabolism and increases energy expenditure This means that not only does Retatrutide regulate blood sugar and suppress appetite like Ozempic it also burns more fat and preserves more muscle while you lose weight

doi: 10.1007/s00204-007-0214-5 32 LupescuA.ShaikN.JilaniK.ZelenakC.LangE.PashamV.et al

Our program specifically addresses the components of metabolic syndrome that accelerate aging: Insulin Resistance : Tirzepatide dramatically improves insulin sensitivity, helping your cells use glucose more efficiently Visceral Fat : Targeted reduction of dangerous abdominal fat that contributes to inflammation Lipid Profiles : Improved cholesterol ratios and triglyceride levels Blood Pressure : Natural reduction through weight loss and improved vascular function The Longevity Benefits You Can Expect Cellular Health and Anti-Aging Early research indicates that tirzepatide, through its effects on GIP and GLP-1 receptors, may offer neuroprotective benefits, potentially lowering the risk of neurodegenerative diseases like Alzheimers